Drugs Monitor, Page 40

(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU

April 27, 2020

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/ Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. In baricitinib-treated patients no adverse events were recorded and clinical and respiratory parameters significantly improved… Continue reading "(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU"

(22 April 2020) Tocilizumab- within 24 h following the tocilizumab infusion, improvement in fever and hypoxaemia observed

April 27, 2020

Case study : a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab https://journals.co.za/content/journal/10520/EJC-1c8cd2727d#abstract_content This report elaborates case of a patient with Covid-19 infection, progressive pneumonia, development of a hyperinflammatory state and cytokine release syndrome… Continue reading "(22 April 2020) Tocilizumab- within 24 h following the tocilizumab infusion, improvement in fever and hypoxaemia observed"

(21 April 2020) Hydroxychloroquine- not found effective in a 368 patients study

April 25, 2020

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1 A retrospective analysis of data from 368 patients hospitalized with confirmed SARSCoV- 2 infection in all United States Veterans Health Administration medical centers reported failure of hydroxychloroquine treatment… Continue reading "(21 April 2020) Hydroxychloroquine- not found effective in a 368 patients study"

(20 April 2020) Hydroxychloroquine- possible side effects

April 24, 2020

Hydroxychloroquine could have side-effects, suggests new study by ICMR https://health.economictimes.indiatimes.com/news/industry/hydroxychloroquine- “A study has been launched to know the side-effects of HCQ. We found that healthcare workers having an average age of 35 years took these drugs and 10% reported abdominal… Continue reading "(20 April 2020) Hydroxychloroquine- possible side effects"

(17 April 2020) Hydroxychloroquine- For prophylaxis for COVID-19 contacts in India

April 24, 2020

Hydroxychloroquine prophylaxis for COVID-19 contacts in India https://doi.org/10.1016/S1473-3099(20)30313-3 The Indian Council of Medical Research, under the Ministry of Health and Family Welfare, has recommended chemoprophylaxis with hydroxychloroquine (400 mg twice on day 1, then 400 mg once a week thereafter)… Continue reading "(17 April 2020) Hydroxychloroquine- For prophylaxis for COVID-19 contacts in India"

(16 April 2020) Ivermectin- Use requires careful risk–benefit considerations

April 24, 2020

Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0271 Extreme due diligence and regulatory review are needed before testing ivermectin in severe disease for following 3 points, Neurotoxicity Concurrent use of antiretrovirals Doses required to reach… Continue reading "(16 April 2020) Ivermectin- Use requires careful risk–benefit considerations"

(16 April 2020) Chloroquine- Study of High-Dose Chloroquine for COVID-19 Stopped Early Due to fatal arrhythmia

April 24, 2020

Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2 The researchers enrolled two groups of COVID-19 patients in a public hospital in Manaus; the high-dose group was assigned a total dose of 12 grams of… Continue reading "(16 April 2020) Chloroquine- Study of High-Dose Chloroquine for COVID-19 Stopped Early Due to fatal arrhythmia"

(15 April 2020) Favipiravir- significantly improved latency to relief for pyrexia and cough

April 23, 2020

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4 In a prospective, randomized, controlled, open-label multicenter trial involving 240 adult patients with COVID-19. Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir… Continue reading "(15 April 2020) Favipiravir- significantly improved latency to relief for pyrexia and cough"

(14 April 2020)- Umifenovir (Arbidol)- shorter duration of positive RNA test

April 23, 2020

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf In the present study, the authors anayzed the efficacy and safety of lopinavir/ritonavir and arbidol monotherapy in patients with COVID-19. On day 14 after the admission, no viral load was… Continue reading "(14 April 2020)- Umifenovir (Arbidol)- shorter duration of positive RNA test"

(13 April 2020) Remdesivir- Late initiation of Remdesivir may be effective

April 23, 2020

Delayed Initiation of Remdesivir in a COVID‐19 Positive Patient https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2403 A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of… Continue reading "(13 April 2020) Remdesivir- Late initiation of Remdesivir may be effective"